HKEX Stock Movement: XtalPi (02228) Surges Over 5% as AI-Driven Drug PEP08 Receives Clinical Trial Approvals, Commercialization of AI Pharma Business Progresses Steadily

According to the Zhongtong Finance APP, XtalPi (02228) rose more than 5%. As of the time of writing, it increased by 5.06%, trading at HK$10.37, with a turnover of HK$964 million.

On the news front, recently, XtalPi announced that a new generation of PRMT5 inhibitor PEP08, which it helped PharmaEngine discover, has reached an important clinical development milestone. PEP08 has recently been approved for clinical trials by the Australian Human Research Ethics Committee (HREC), the Australian Therapeutic Goods Administration (TGA), and Taiwan's "Health and Welfare Ministry Food and Drug Administration" (TFDA), marking the upcoming launch of Phase I clinical trials for the drug. Based on this progress, XtalPi confirmed receipt of the project’s milestone payment.

CMB Securities pointed out that XtalPi's AI pharmaceutical business commercialization is proceeding steadily, with a year-on-year growth rate of 615% in its drug discovery business by the first half of 2025. XtalPi maintains long-term cooperation with several global top pharmaceutical companies such as Pfizer and Johnson & Johnson. The company has completed pipeline cooperation agreements totaling $5.99 billion with DoveTree and has received the first payment of $51 million stipulated in the agreement, contributing to performance growth. By sharing quantum physics computing, multimodal AI, and automation platforms, XtalPi has achieved cross-domain reuse of its technology platform, successfully expanding into multiple fields including new energy, agriculture, and industrial materials.